{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,23]],"date-time":"2025-10-23T10:55:46Z","timestamp":1761216946047},"reference-count":10,"publisher":"Wiley","issue":"4","license":[{"start":{"date-parts":[[2005,7,19]],"date-time":"2005-07-19T00:00:00Z","timestamp":1121731200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Brit J Clinical Pharma"],"published-print":{"date-parts":[[2005,10]]},"abstract":"<jats:sec><jats:title>Aims<\/jats:title><jats:p>To assess the relative toxicity of co\u2010proxamol in overdose in comparison to the 2 other paracetamol\u2010opioid combination products, co\u2010codamol and co\u2010dydramol.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Data collected over a 2\u2010year period (July 2000\u2013June 2002) was used to estimate the frequency of overdose and death for the three most popular paracetamol\u2010opioid compound analgesics. Prescription data for Scotland and Edinburgh, the number of overdoses (derived from overdose admissions in Edinburgh) or Poisons Information Service contacts in Scotland, and national death records were used to calculate a series of indicators relating morbidity (admissions), surrogates of morbidity (poisons enquiries by telephone or internet) and mortality to prescriptions.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>When related to prescription volume overdoses involving co\u2010proxamol in Scotland were 10 times more likely to be fatal (24.6 (19.7, 30.4)) when compared with co\u2010codamol (2.0 (0.88, 4.0)) or co\u2010dydramol (2.4 (0.5, 7.2)). In contrast there was no difference in the presentation rate or enquiry rates for these analgesics when corrected for prescriptions.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>The excess hazard from co\u2010proxamol is due to inherent toxicity rather than increased use in overdose. We estimate from this study that withdrawal of co\u2010proxamol would prevent 39 excess deaths per annum in Scotland alone.<\/jats:p><\/jats:sec>","DOI":"10.1111\/j.1365-2125.2005.02468.x","type":"journal-article","created":{"date-parts":[[2005,9,27]],"date-time":"2005-09-27T13:37:34Z","timestamp":1127828254000},"page":"444-447","source":"Crossref","is-referenced-by-count":26,"title":["Co\u2010proxamol overdose is associated with a 10\u2010fold excess mortality compared with other paracetamol combination analgesics"],"prefix":"10.1111","volume":"60","author":[{"given":"R.","family":"Afshari","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.M.","family":"Good","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.R.J.","family":"Maxwell","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D.N.","family":"Bateman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2005,7,19]]},"reference":[{"key":"e_1_2_6_2_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.326.7397.1006"},{"key":"e_1_2_6_3_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2125.2004.02252.x"},{"key":"e_1_2_6_4_2","unstructured":"Medicines and Healthcare products Regulatory Agency. Co\u2010proxamol to be withdrawn from the market.http:\/\/www.mhra.gov.uk\/Co\u2010proxamolwithdrawal. 31 Jan 2005."},{"key":"e_1_2_6_5_2","doi-asserted-by":"publisher","DOI":"10.2165\/00002018-199818050-00006"},{"key":"e_1_2_6_6_2","doi-asserted-by":"publisher","DOI":"10.1177\/096032718400300116"},{"key":"e_1_2_6_7_2","doi-asserted-by":"publisher","DOI":"10.2165\/00003495-198326010-00004"},{"key":"e_1_2_6_8_2","volume-title":"Therapeutic drugs","author":"Dollery CT","year":"1999"},{"key":"e_1_2_6_9_2","first-page":"476","article-title":"ECG abnormalities in co\u2010proxamol (paracetamol\/dextropropoxyphene) poisoning compared with co\u2010codamol and co\u2010dydramol","volume":"42","author":"Afshari R","year":"2004","journal-title":"J Toxicol Clin Toxicol"},{"key":"e_1_2_6_10_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.315.7122.1565"},{"key":"e_1_2_6_11_2","first-page":"141","article-title":"Dextropropoxyphene deaths in Denmark from the health authority point of view","volume":"12","author":"Segest E","year":"1993","journal-title":"Med Law"}],"container-title":["British Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1365-2125.2005.02468.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/bpspubs.onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1365-2125.2005.02468.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,16]],"date-time":"2023-10-16T02:44:54Z","timestamp":1697424294000},"score":1,"resource":{"primary":{"URL":"https:\/\/bpspubs.onlinelibrary.wiley.com\/doi\/10.1111\/j.1365-2125.2005.02468.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,7,19]]},"references-count":10,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2005,10]]}},"alternative-id":["10.1111\/j.1365-2125.2005.02468.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1365-2125.2005.02468.x","archive":["Portico"],"relation":{},"ISSN":["0306-5251","1365-2125"],"issn-type":[{"value":"0306-5251","type":"print"},{"value":"1365-2125","type":"electronic"}],"subject":[],"published":{"date-parts":[[2005,7,19]]}}}